Acquired Immune Deficiency Syndrome Virus, HIV Infections
Conditions
Keywords
AIDS, complementary therapies
Brief summary
The average period of asymptomatic HIV-infection is 8 years, at this stage, CD4+ T lymphocyte count was reduced gradually at the rate of 50\ 100cells/ul/year. When the CD4 T lymphocyte count dropped below 350cells/ul and viral load increased to 105 in AIDS patients, HAART will be carried out. But, CD4 T lymphocyte was 350\ 550 cells/ul, there is no intervention measures.
Detailed description
* The average period of asymptomatic HIV-infection is 8 years, at this stage, CD4+ T lymphocyte count was reduced gradually at the rate of 50\ 100cells/ul/year. When the CD4 T lymphocyte count dropped below 350cells/ul and viral load increased to 105 in AIDS patients, HAART will be carried out. But, CD4 T lymphocyte was 350\ 550 cells/ul, there is no intervention measures. * Immunity 1 (Fuzheng 1) is composed of herbs which have tonic and detoxific function. The long-term clinical application has proved the safety and effect. It can improve the symptoms and signs in AIDS patients with the effective rate of 70% and can significantly improve the quality of life. It can also improve and stabilize immune function and inhibit viral replication. The basis study have shown that Immunity 1 (Fuzheng 1) can inhibit viral replication from multi-target, multi-link, enhance immune function, increase the secretion of IL-2, IFN-γ, participate in immune regulation effect, enhance NK cell activity, promote CD3+CD4+T cell proliferation and increase macrophage phagocytes capacity. * Through the clinical trials, we are going to evaluate the efficacy and safety of Immunity 1 (Fuzheng 1) on immune reconstitution of HIV patients in WHOⅠ、II period.
Interventions
DRUGFuzheng 1
Immunity 1 (Fuzheng 1), 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
DRUGPlacebo
Placebo, 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Sponsors
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* HIV antibody-positive, confirmed by Western Blot test * CD 4 counts\> 350 cells / ul and \<550 cells / ul * Age ≥ 18 years old and ≤ 70 years old * Voluntary participated in this study, signed informed consent form, and could be followed-up
Exclusion criteria
* Patients in WHO clinical stage Ⅲ, Ⅳ * Participated in clinical trials of other drugs within one month before the experiment * Received antiretroviral therapy or are anti-HIV drugs such as nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs) and fusion-inhibiting agent (FIs), integrase inhibitors, inhibitors penetration within one month before the experiment * Received immunomodulatory treatment within one month before the experiment Liver and kidney dysfunction (AST, ALT, T-BIL ≥2 times of upper limit of the reference value or creatinine ≥ 2 times of the upper limit of reference value) * Patients with obvious active diseases in respiratory system, digestive system, circulatory system, blood system, neuroendocrine system, or genitourinary system diseases * Persons suffering from autoimmune diseases * Cancer patients which need chemotherapy * Pregnant or lactating women, and did not use safe contraceptive measures for women of child-bearing age, as well as the male that can not take a reasonable method of contraception in trial period * Hypersensitive people * Patients with dysgnosia or language barriers, which can not fully understand the test or cooperate well
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Peripheral blood CD3+ CD4+ counts | 6 months |
Secondary
| Measure | Time frame |
|---|---|
| Viral load | 6 months |
| Clinical symptoms and signs | 6 months |
| KPS score | 6 months |
| Immune reconstitution efficiency | 6 months |
| Safety evaluation | 6 months |
| Economic evaluation | 6 months |
| Quality of life score | 6 months |
Countries
China
Contacts
Primary ContactJie LIU
Outcome results
None listed